Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1

Gene Therapy

Volumn 18, Issue 2, 2011, Pages 164-172

  Huang, B ^a   Sikorski, R ^a   Kirn, D H ^b   Thorne, S H ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Jennerex Biotherapeutics   (United States)

Author keywords

HMGB1; interferon; oncolytic virus; paclitaxel; synergy

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INTERFERON; ONCOLYTIC VIRUS; PACLITAXEL; TAXANE DERIVATIVE; VACCINIA VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; DATA ANALYSIS; DRUG SENSITIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MEDICAL RECORD; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; VACCINIA VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HMGB1 PROTEIN; HUMANS; INTERFERONS; MICE; MICE, NUDE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PACLITAXEL; VACCINIA VIRUS;

VACCINIA VIRUS;

EID: 79951508366     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.121     Document Type: Article

References (36)

1. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785: 217-231. Epub 15 Feb 2008.
2. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64-71.
3. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533-542.
4. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008; 14: 7127-7137.
5. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70: 875-882.
6. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771.
7. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008; 10: 371-379.
8. Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 2008; 10: 362-370.
9. Nguyen TL, Tumilasci VF, Singhroy D, Arguello M, Hiscott J. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cell Microbiol 2009; 11: 889-897.
10. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005; 12: 437-445. (Pubitemid 40394296)
11. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000; 7: 588-592.
12. Gutermann A, Mayer E, von Dehn-Rothfelser K, Breidenstein C, Weber M, Muench M et al. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther 2006; 17: 1241-1253. (Pubitemid 44975140)
13. Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007; 13: 7155-7165. (Pubitemid 350276902)
14. Abou El, Hassan MA, Braam SR, Kruyt FA. Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells. Cancer Gene Ther 2006; 13: 1105-1114. (Pubitemid 44760108)
15. Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther 2009; 16: 551-560.
16. Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 2008; 68: 3795-3802.
17. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002; 83: 2615-2631.
18. Wali A, Strayer DS. Infection with vaccinia virus alters regulation of cell cycle progression. DNA Cell Biol 1999; 18: 837-843.
19. Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994; 54: 4355-4361. (Pubitemid 24273147)
20. Carter GC, Rodger G, Murphy BJ, Law M, Krauss O, Hollinshead M et al. Vaccinia virus cores are transported on microtubules. J Gen Virol 2003; 84: 2443-2458. (Pubitemid 37063134)
21. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010; 1799: 149-156.
22. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101: 296-301. (Pubitemid 38084244)
23. Chung CS, Hsiao JC, Chang YS, Chang W. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol 1998; 72: 1577-1585. (Pubitemid 28116945)
24. Hsiao JC, Chung CS, Chang W. Cell surface proteoglycans are necessary for A27 L protein-mediated cell fusion: identification of the N-terminal region of A27L protein as the glycosaminoglycan-binding domain. J Virol 1998; 72: 8374-8379. (Pubitemid 28421842)
25. Moreira CR, Lopes CC, Cuccovia IM, Porcionatto MA, Dietrich CP, Nader HB. Heparan sulfate and control of endothelial cell proliferation: increased synthesis during the S phase of the cell cycle and inhibition of thymidine incorporation induced by ortho-nitrophenyl-beta-D-xylose. Biochim Biophys Acta 2004; 1673: 178-185. (Pubitemid 38981771)
26. Tough DF. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 2004; 45: 257-264. (Pubitemid 38181426)
27. Schneider B, Fukunaga A, Murry D, Yoder C, Fife K, Foster A et al. A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors. Cancer Chemother Pharmacol 2007; 59: 261-268. (Pubitemid 44885155)
28. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007; 4: e353.
29. Symons JA, Alcami A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995; 81: 551-560.
30. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53-71.
31. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342. (Pubitemid 40516158)
32. Tang D, Kang R, Zeh 3rd HJ, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799: 131-140.
33. Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008; 20: 518-523.
34. Zhuang W, Qin Z, Liang Z. The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 341-351.
35. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751-8757. (Pubitemid 34013887)
36. Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, Kirn D et al. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immuno-competent tumor models. Cancer Gene Ther 2008; 15: 40-50. (Pubitemid 350261299)